Eledon Pharmaceuticals, Inc. Cash Flow Statement
ELDN|3 years of annual SEC 10-K data (FY2014-FY2016)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Eledon Pharmaceuticals, Inc. used $21M in operating cash flow and negative free cash flow of $21M in FY2016.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2016 | FY2015 | FY2014 |
|---|---|---|---|
| Net Income | -$23.3M | -$15.7M | -$9.6M |
| Depreciation & Amortization | $21.0K | $10.0K | $9.0K |
| Operating Cash Flow | -$21.1M | -$15.5M | -$9.3M |
| Capital Expenditures | $25.0K | $23.0K | $8.0K |
| Free Cash Flow | -$21.1M | -$15.5M | -$9.3M |